Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PLRZ Catalyst Timeline
Dated clinical, regulatory and corporate events for Polyrizon Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Polyrizon Ltd.
Upcoming catalysts 2
Past FDA Catalysts and PDUFA Decisions
How PLRZ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Polyrizon Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PLRZ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| naloxone | 2026-02-26 | significantly higher deposition in the nasal vestibule region compared to the commercial reference productRead More | Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference ProductRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Adler OzDirector | Sell | -3,292 19,850 held | $12.05 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PLRZ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PLRZ for Q3 2026. | ||||
Ownership Trends
PLRZ Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How PLRZ ranks across every disease it competes in
PLRZ News
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
Polyrizon Ltd. has adopted a limited duration shareholder rights plan to protect its shareholders amid ongoing trading price dislocation. The plan, effective immediately, aims to ensure that any potential acquirer negotiates directly with the Board before attempting to gain control. It will be submitted for ratification at the next shareholder meeting.
Read more →Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Polyrizon has completed the enrollment of 120 participants in its U.S. clinical study of NASARIX, an investigational nasal hydrogel designed to protect against airborne allergens. The study aims to evaluate NASARIX's effectiveness in managing allergic rhinitis symptoms. The company plans to proceed with data analysis following the treatment and follow-up periods.
Read more →Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
Polyrizon Ltd. has filed a new U.S. divisional patent application to enhance its intellectual property related to its mucoadhesive technology for nasal drug delivery. This application is part of a broader patent family aimed at supporting various therapeutic applications through mucosal tissues. The CEO highlighted the potential of the technology beyond barrier applications, focusing on therapeutic delivery.
Read more →Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
Polyrizon has enrolled its first patient in a U.S. clinical study for NASARIX (PL-14), an investigational allergy blocker for seasonal allergic rhinitis. This marks a pivotal transition for the company into clinical development. The study aims to evaluate the efficacy, safety, and tolerability of NASARIX compared to a saline nasal spray in 120 patients.
Read more →Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Polyrizon Ltd. has closed a $4.0 million registered direct offering and private placement, issuing shares and warrants to a single institutional investor. The funds raised will be utilized for general corporate purposes and working capital. The transactions included the issuance of Ordinary Shares and pre-funded warrants, with a combined offering price of $12.00 per unit.
Read more →Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
Polyrizon Ltd. has announced a $4.0 million registered direct offering and private placement with a single institutional investor. The offering includes the sale of Ordinary Shares and pre-funded warrants, expected to close on September 4, 2026. The proceeds will be used for corporate purposes and working capital, enhancing the company's innovative hydrogel technology.
Read more →Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
Polyrizon Ltd. has successfully completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker study. This first-in-human trial aims to assess the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis. The study will enroll up to 120 patients and is set to begin patient pre-screening and enrollment activities.
Read more →Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Polyrizon Ltd. has completed contracting with all five clinical sites for its NASARIX™ study, which aims to enroll 120 patients with seasonal allergic rhinitis. The study will evaluate the efficacy, safety, and tolerability of NASARIX™ compared to a saline control. With patient pre-screening underway, enrollment is timed to coincide with relevant allergy seasons.
Read more →Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Polyrizon Ltd. announced successful results from its biocompatibility evaluation program for NASARIXTM, a drug-free nasal spray aimed at reducing exposure to allergens. The program met all biological safety tests and was conducted in accordance with international standards. This milestone supports the product's advancement towards clinical trials and potential commercialization.
Read more →Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Polyrizon Ltd. has received central IRB approval for its first human clinical trial of NASARIX, a nasal spray designed to block airborne allergens. The approval, granted by the BRANY Institutional Review Board, confirms that the study protocol meets ethical and participant protection standards. The trial will evaluate NASARIX's efficacy compared to a saline spray in patients with seasonal allergic rhinitis.
Read more →Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
Polyrizon Ltd. has announced the publication of a U.S. patent application for its Trap & Target™ mucoadhesive polymer technology aimed at enhancing nasal drug delivery. This platform is designed to improve drug absorption and retention through the nasal mucosa, potentially benefiting various therapeutic applications. The technology combines biocompatible polymers to create effective formulations for both localized and systemic drug delivery.
Read more →Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
Polyrizon Ltd. has partnered with a prominent European medical center to conduct a human study on its NASARIX™ allergy blocker. This study will assess the nasal residence time of the formulation, which is crucial for understanding its protective barrier function. The findings are expected to support the company's regulatory strategy, including submissions to the FDA.
Read more →Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Polyrizon Ltd. announced the publication of its European patent application for its innovative mucoadhesive polymer technology aimed at enhancing nasal drug delivery. This technology seeks to improve drug absorption and retention time in the nasal cavity, addressing key challenges in the field. The patent publication is a significant milestone for Polyrizon as it strengthens its intellectual property portfolio and supports future pharmaceutical collaborations.
Read more →Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Ltd. has announced the addition of two new U.S. clinical sites for its NASARIX™ trial, bringing the total to three. These sites are crucial for the planned multi-center study evaluating the safety and efficacy of the NASARIX™ Allergy Blocker for seasonal allergic rhinitis. The company is optimistic about efficient patient recruitment and timely trial execution.
Read more →Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Polyrizon Ltd. has signed a Clinical Trial Agreement with a U.S. clinical site, marking a significant step towards human clinical trials for its NASARIX™ Allergy Blocker. The study will assess the safety, tolerability, and efficacy of the nasal spray in patients suffering from seasonal allergic rhinitis. This multi-center trial is expected to adhere to international Good Clinical Practice standards.
Read more →Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
Polyrizon Ltd. has announced the submission of amended claims for its U.S. patent application, expanding the scope of its intranasal drug delivery platform. The new claims include drug delivery systems and methods aimed at improving medication effectiveness. This move is part of Polyrizon's strategy to enhance its global intellectual property portfolio and potentially improve treatment outcomes across various therapeutic areas.
Read more →Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
Polyrizon Ltd. has filed a divisional patent application with the European Patent Office for its innovative Trap & Target (T&T) intranasal drug delivery platform. This technology aims to enhance the bioavailability of medications and address challenges in drug delivery. The filing reinforces Polyrizon's commitment to protecting its intellectual property and advancing healthcare solutions.
Read more →Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
Polyrizon Ltd. has successfully closed a $3.5 million registered direct offering and private placement with a single institutional investor. The offering included Ordinary Shares and pre-funded warrants, with proceeds aimed at supporting general corporate purposes. The company anticipates having over 2 million Ordinary Shares outstanding following the offering.
Read more →Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
Polyrizon Ltd. has announced a $3.5 million registered direct offering and private placement with a single institutional investor. The transactions involve the sale of Ordinary Shares and pre-funded warrants, with expected proceeds to be used for corporate purposes. The offering is set to close around April 8, 2026, pending customary conditions.
Read more →Polyrizon Provides 2025 and Recent Highlights
Polyrizon Ltd. has reported significant advancements in its intranasal protective solutions, including successful FDA meetings and preclinical results. The company is preparing for potential human clinical trials and has established collaborations to support its clinical development. With a strong cash position and a debt-free balance sheet, Polyrizon is well-positioned for future growth.
Read more →